traveling with compounded tirzepatide Travel Tirzepatide: Medical Planning Guide – PlexusDx Replying to @Belakruse How to

Lilly has since submitted orforglipron to the FDA for the treatment of obesity

64 ElderG

In secondary analyses within the GLP-1RA group, continued use was compared with the other scenarios

There are a handful of reasons: 1) Obesity : 1 in 8 is obese worldwide, doubled since 1990 2) Usage : increasing into apnea, kidney and heart health, in testing for cancer & addiction 3) Ease : pills will bring down costs and increase usage 4) Innovation : new drugs bring greater weight loss, fewer side effects and unique action 5) Cost : pills, generics, subsidies, insurance and increased competitors all drive price down Q: Is GLP-1 a trend that is likely to stay or is the bubble about to burst